Cencora Inc.

09/24/2025 | Press release | Distributed by Public on 09/25/2025 12:44

Cencora to Support Commercial Launch of Precigen’s Novel Immunotherapy in the United States

Cencora
, a global pharmaceutical solutions organization, has been selected by Precigen Inc. , to provide comprehensive logistics and distribution services to support the commercial launch of Precigen's novel immunotherapy in the United States.

The U.S. Food and Drug Administration recently approved the first-of-its-kind non-replicating adenoviral vector-based immunotherapy for the treatment of adult patients with recurrent respiratory papillomatosis (RRP).

Cencora will provide integrated order-to-cash, third-party-logistics (3PL) and specialty logistics services - including temperature-controlled solutions - to support secure storage and distribution. Through its integrated support, including the use of a flash title model, Cencora aims to simplify and streamline processes for sites of care, enabling efficient and reliable access to therapies.

"Precision medicines require heightened collaboration and flawless execution across the supply chain - from the moment a patient is identified through to delivery to the site of care and patient administration," said Kevin Chinn, Vice President and Head of Cell & Gene Therapy Service Line at Cencora. "Through our partnership with Precigen, we'll deliver the support needed to safeguard product integrity throughout storage and transport and simplify critical processes for sites of care, enabling safe and timely deliveries to healthcare providers and the patients they serve."

Cencora Inc. published this content on September 24, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 25, 2025 at 18:44 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]